GlassScriptPhysician profile
Charles Robert Campbell
NPI 1437592383
$2,442.51
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $76.53 · 2021: $134 · 2022: $187 · 2023: $739 · 2024: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.67 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.02 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $255.21 | 2019-2023 | Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $230.50 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $201.76 | 2019-2024 | Rexulti |
| Pfizer INC. | $188.08 | 2019-2024 | |
| Glaxosmithkline, LLC. | $161.42 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $152.61 | 2019-2023 | Qulipta, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $110.06 | 2019-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $106.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.82 | 2022-2024 | |
| Amgen INC. | $91.23 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $73.84 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $65.09 | 2023-2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $61.67 | 2024 | Rytary, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $57.48 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.90 | 2019 | |
| Collegium Pharmaceutical, INC. | $38.80 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $32.00 | 2024 | Zoryve |
| Astellas Pharma US INC | $30.28 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $30.01 | 2020-2021 | |
| Sanofi Pasteur INC. | $24.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.50 | 2023 | |
| Daiichi Sankyo INC. | $18.18 | 2019 | |
| Phadia US INC. | $16.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.49 | 2019 | |
| Dexcom, INC. | $14.69 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $14.05 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.